Evolus (EOLS) Income from Continuing Operations (2017 - 2026)
Evolus (EOLS) reported Income from Continuing Operations of 10674000.0 for Q1 2026, up 43.5% on a YoY basis from 7438333.01 in Q1 2025, and down 8310.77% quarter-over-quarter from 130000.0 in Q4 2025.
Evolus (EOLS) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Evolus has reported Income from Continuing Operations for 10 years, with the latest figure at 10674000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 43.5% year-over-year to 10674000.0; the trailing twelve-month figure through Mar 2026 stood at 43423000.0 (up 22.74% YoY), and the FY2025 full-year result was 51641000.0, down 2.42% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 10674000.0, down from 130000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 130000.0 in Q4 2025, with the low at 23471000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 14637176.47 across 5 years, with a median of 15737000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 373.41% — and 2025, when it soared 101.91%.
- Evolus' Income from Continuing Operations stood at 13164000.0 in 2022, then rose by 10.13% to 11831000.0 in 2023, then jumped by 42.6% to 6791000.0 in 2024, then surged by 101.91% to 130000.0 in 2025, then slumped by 8310.77% to 10674000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 10674000.0 (Q1 2026), 130000.0 (Q4 2025), and 15737000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Evolus | 435.45 Mn | 385.65 Mn | 48.90 Mn | -10.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.67 Mn |
| Dec 31, 2025 | 130,000.00 |
| Sep 30, 2025 | -15.74 Mn |
| Jun 30, 2025 | -17.14 Mn |
| Mar 31, 2025 | -18.89 Mn |
| Dec 31, 2024 | -6.79 Mn |
| Sep 30, 2024 | -19.17 Mn |
| Jun 30, 2024 | -11.35 Mn |
| Mar 31, 2024 | -13.11 Mn |
| Dec 31, 2023 | -11.83 Mn |
| Sep 30, 2023 | -16.92 Mn |
| Jun 30, 2023 | -18.14 Mn |
| Mar 31, 2023 | -14.79 Mn |
| Dec 31, 2022 | -13.16 Mn |
| Sep 30, 2022 | -20.28 Mn |
| Jun 30, 2022 | -23.47 Mn |
| Mar 31, 2022 | -17.50 Mn |
| Dec 31, 2021 | -18.18 Mn |
| Sep 30, 2021 | -19.43 Mn |
| Jun 30, 2021 | -15.60 Mn |